FI20090161A0 - Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä - Google Patents

Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä

Info

Publication number
FI20090161A0
FI20090161A0 FI20090161A FI20090161A FI20090161A0 FI 20090161 A0 FI20090161 A0 FI 20090161A0 FI 20090161 A FI20090161 A FI 20090161A FI 20090161 A FI20090161 A FI 20090161A FI 20090161 A0 FI20090161 A0 FI 20090161A0
Authority
FI
Finland
Prior art keywords
therapeutical
methods based
diagnostic methods
new cell
diagnostic
Prior art date
Application number
FI20090161A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Priority to FI20090161A priority Critical patent/FI20090161A0/fi
Publication of FI20090161A0 publication Critical patent/FI20090161A0/fi
Priority to CA3022659A priority patent/CA3022659C/en
Priority to PL10766694T priority patent/PL2421888T3/pl
Priority to PCT/FI2010/050266 priority patent/WO2010122217A1/en
Priority to PT107666943T priority patent/PT2421888T/pt
Priority to LTEP10766694.3T priority patent/LT2421888T/lt
Priority to NO10766694A priority patent/NO2421888T3/no
Priority to ES10766694.3T priority patent/ES2666185T3/es
Priority to DK10766694.3T priority patent/DK2421888T3/en
Priority to US13/262,088 priority patent/US8722045B2/en
Priority to JP2012506538A priority patent/JP5819285B2/ja
Priority to HUE10766694A priority patent/HUE037394T2/hu
Priority to CA2757706A priority patent/CA2757706C/en
Priority to EP10766694.3A priority patent/EP2421888B1/de
Priority to SI201031666T priority patent/SI2421888T1/en
Priority to EP17197919.8A priority patent/EP3330281A1/de
Priority to US14/224,374 priority patent/US10526607B2/en
Priority to JP2015150694A priority patent/JP6141919B2/ja
Priority to HRP20180580TT priority patent/HRP20180580T1/hr
Priority to CY20181100423T priority patent/CY1120175T1/el
Priority to HK18115414.6A priority patent/HK1256330A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
FI20090161A 2009-04-22 2009-04-22 Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä FI20090161A0 (fi)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FI20090161A FI20090161A0 (fi) 2009-04-22 2009-04-22 Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
EP17197919.8A EP3330281A1 (de) 2009-04-22 2010-04-06 Clever-1 levels als marker für eine verbesserte anti-tumor antwort
DK10766694.3T DK2421888T3 (en) 2009-04-22 2010-04-06 CLEVER-1 receptor antagonists to block immune-inhibitory type 2 macrophages
JP2012506538A JP5819285B2 (ja) 2009-04-22 2010-04-06 子癇前症の検出を補助する方法またはそのリスクの推定を補助する方法
PCT/FI2010/050266 WO2010122217A1 (en) 2009-04-22 2010-04-06 A novel cell and therapeutical and diagnostical methods based thereon
PT107666943T PT2421888T (pt) 2009-04-22 2010-04-06 Antagonistas do recetor clever-1 para bloqueamento de macrófagos de tipo 2 imunoinibidores
LTEP10766694.3T LT2421888T (lt) 2009-04-22 2010-04-06 Clever-1 receptorių antagonistai, skirti blokuoti imunitetą slopinančius 2 tipo makrofagus
NO10766694A NO2421888T3 (de) 2009-04-22 2010-04-06
ES10766694.3T ES2666185T3 (es) 2009-04-22 2010-04-06 Antagonistas del receptor CLEVER-1 para bloquear los macrófagos inmuno-inhibidores de tipo 2
CA3022659A CA3022659C (en) 2009-04-22 2010-04-06 A novel cell and therapeutical and diagnostical methods based thereon
US13/262,088 US8722045B2 (en) 2009-04-22 2010-04-06 Cell and therapeutical and diagnostical methods based thereon
PL10766694T PL2421888T3 (pl) 2009-04-22 2010-04-06 Antagoniści receptora clever-1 do blokowania makrofagów typu 2 hamujących układ immunologiczny
HUE10766694A HUE037394T2 (hu) 2009-04-22 2010-04-06 Clever-1 receptor antagonisták immun-gátló 2 típusú makrofágok blokkolására
CA2757706A CA2757706C (en) 2009-04-22 2010-04-06 A novel cell and therapeutical and diagnostical methods based thereon
EP10766694.3A EP2421888B1 (de) 2009-04-22 2010-04-06 CLEVER-1 Rezeptor Antagonisten zur Hemmung immun-inhibitorischer Typ 2 Makrophagen.
SI201031666T SI2421888T1 (en) 2009-04-22 2010-04-06 CLEVER-1 receptor antagonists for blocking immunomodulatory macrophages of type 2.
US14/224,374 US10526607B2 (en) 2009-04-22 2014-03-25 Cell and therapeutical and diagnostical methods based thereon
JP2015150694A JP6141919B2 (ja) 2009-04-22 2015-07-30 新規細胞上のＣｌｅｖｅｒ−１をモジュレートし得る医薬組成物
HRP20180580TT HRP20180580T1 (hr) 2009-04-22 2018-04-11 Antagonisti receptora clever-1, namijenjeni blokiranju makrofaga imunoinhibicijskog tipa 2
CY20181100423T CY1120175T1 (el) 2009-04-22 2018-04-23 Ανταγωνιστες υποδοχεα clever-1 για αποκλεισμο των ανοσο-ανασταλτικων μακροφαγων τυπου 2
HK18115414.6A HK1256330A1 (zh) 2009-04-22 2018-12-03 作為抗腫瘤響應提高的標記物的clever-1水平

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20090161A FI20090161A0 (fi) 2009-04-22 2009-04-22 Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä

Publications (1)

Publication Number Publication Date
FI20090161A0 true FI20090161A0 (fi) 2009-04-22

Family

ID=40590220

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20090161A FI20090161A0 (fi) 2009-04-22 2009-04-22 Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä

Country Status (17)

Country Link
US (2) US8722045B2 (de)
EP (2) EP2421888B1 (de)
JP (2) JP5819285B2 (de)
CA (2) CA2757706C (de)
CY (1) CY1120175T1 (de)
DK (1) DK2421888T3 (de)
ES (1) ES2666185T3 (de)
FI (1) FI20090161A0 (de)
HK (1) HK1256330A1 (de)
HR (1) HRP20180580T1 (de)
HU (1) HUE037394T2 (de)
LT (1) LT2421888T (de)
NO (1) NO2421888T3 (de)
PL (1) PL2421888T3 (de)
PT (1) PT2421888T (de)
SI (1) SI2421888T1 (de)
WO (1) WO2010122217A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102403660B1 (ko) * 2016-04-18 2022-05-30 파론 파머수티컬스 오와이 CLEVER-1, TNF-α 및 HLA-DR 결합제를 사용하는 면역 활성화의 진단
LT3445785T (lt) 2016-04-18 2022-10-10 Faron Pharmaceuticals Oy Humanizuoti anti clever-1 antikūnai ir jų naudojimas
JP7081343B2 (ja) 2018-07-02 2022-06-07 カシオ計算機株式会社 押釦装置、押釦装置に適用される緩衝部材及び時計
CA3113895A1 (en) 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
WO2021100891A1 (ko) * 2019-11-19 2021-05-27 경상대학교병원 구강암 예후 진단용 조성물 및 키트
FI129383B (en) 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy STABLE ANTI-CLEVER-1 ANTIBODY FORMULATION
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
WO2023105118A1 (en) * 2021-12-07 2023-06-15 Faron Pharmaceuticals Oy Method for using inflammatory markers to guide anti-clever-1 cancer treatment
WO2023222952A1 (en) * 2022-05-20 2023-11-23 Faron Pharmaceuticals Oy Method for identifying cancer patients that benefit from anti-clever-1 treatment
WO2023222953A1 (en) * 2022-05-20 2023-11-23 Faron Pharmaceuticals Oy Method for identifying cancer patients that benefit from anti-clever-1 treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
AU2001253140A1 (en) * 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
CA2468888C (en) * 2002-01-09 2013-03-12 Sirpa Jalkanen Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
CA2500468A1 (en) 2002-09-28 2004-04-08 Massachussets Institute Of Technology Influenza therapeutic
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050043266A1 (en) 2003-07-25 2005-02-24 Sumedha Jayasena Short interfering RNA as an antiviral agent for hepatitis C
EP1661915A1 (de) 2004-11-25 2006-05-31 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Herstellung von Antikörpern gegen menschlichen Chitinaseartigen Protein GL008
FI20050640A0 (fi) 2005-06-16 2005-06-16 Faron Pharmaceuticals Oy Yhdisteitä amiinioksidaasista riippuvien sairauksien tai häiriöiden hoitoon tai estoon
EP1889922A1 (de) * 2006-08-18 2008-02-20 Burdach, Stefan Verfahren zur Diagnose von pädiatrischer gewöhnlicher akuter Leukämie durch Bestimmung von Genexpressionsniveaus
WO2008097908A2 (en) * 2007-02-05 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and prognosing lung cancer
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof

Also Published As

Publication number Publication date
US20140294760A1 (en) 2014-10-02
SI2421888T1 (en) 2018-06-29
JP6141919B2 (ja) 2017-06-07
EP2421888A4 (de) 2013-03-06
CA2757706A1 (en) 2010-10-28
WO2010122217A1 (en) 2010-10-28
EP2421888B1 (de) 2018-02-21
PT2421888T (pt) 2018-05-09
US8722045B2 (en) 2014-05-13
JP5819285B2 (ja) 2015-11-24
CY1120175T1 (el) 2018-12-12
JP2012524536A (ja) 2012-10-18
CA2757706C (en) 2019-01-15
US10526607B2 (en) 2020-01-07
US20120027770A1 (en) 2012-02-02
HUE037394T2 (hu) 2018-08-28
PL2421888T3 (pl) 2018-07-31
EP2421888A1 (de) 2012-02-29
DK2421888T3 (en) 2018-05-22
ES2666185T3 (es) 2018-05-03
NO2421888T3 (de) 2018-07-21
EP3330281A1 (de) 2018-06-06
HK1256330A1 (zh) 2019-09-20
LT2421888T (lt) 2018-05-25
JP2016020351A (ja) 2016-02-04
CA3022659C (en) 2021-04-06
CA3022659A1 (en) 2010-10-28
HRP20180580T1 (hr) 2018-06-29

Similar Documents

Publication Publication Date Title
FI20090161A0 (fi) Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
BR112012025762A2 (pt) dispositivo de injeção de eletrólito e método de injeção de eletrólito
BRPI1014404A2 (pt) cânula dotada de recurso de cânula e recurso de encaixe em sobreposição
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BRPI1013655A8 (pt) dispositivo e método cirúrgico
BR112012011910A2 (pt) dispositivo e método
DK3718922T3 (da) Glucoseovervågningssystem og fremgangsmåde
BR112013013584A2 (pt) endoscópio, e, método
DK2427107T3 (da) Elektrodefikseringsindretning
BRPI1008917A2 (pt) dispositivo de exibição e método de exibição
BR112012027159A2 (pt) estrutura e método
BRPI0906094A2 (pt) composto e método de tratamento de diabetes do tipo ii
BR112012014996A2 (pt) método diagnóstico baseado em reaaranjo somaticamente adquirido
BRPI0915822A2 (pt) dispositivo médico
BRPI0916551A2 (pt) dispositivo eletroquímico
NO20080778L (no) Kraftelementarrangement og -fremgangsmate
DK2245463T3 (da) Diagnostisk fremgangsmåde
FI20095645A (fi) Ohut paristo
BRPI1007909A2 (pt) método e dispositivo médico
IT1401283B1 (it) Strumento e metodo oftalmico
BRDI7106698S (pt) Configuração aplicada em instrumento médico
BR112013011743A2 (pt) dispositivo de redução de gel e método de redução de gel
BRPI1010215A2 (pt) dispositivo e método
GB0905076D0 (en) Diagnostic kits and methods
BRDI7103033S (pt) Configuração aplicada em instrumento médico

Legal Events

Date Code Title Description
FD Application lapsed